
<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="UTF-8" />
  <meta name="viewport" content="width=device-width, initial-scale=1.0" />
  <title>Drug Discovery Pipeline Knowledge Base</title>
  <link rel="stylesheet" href="styles.css" />
</head>
<body>
  <header>
    <h1>Drug Discovery Pipeline Knowledge Base</h1>
    <p>Comprehensive guide to the stages of drug development</p>
  </header>
  <nav>
    <ul>
      <li><a href="target_identification.html">Target Identification</a></li>
      <li><a href="hit_discovery.html">Hit Discovery</a></li>
      <li><a href="lead_optimization.html">Lead Optimization</a></li>
      <li><a href="preclinical.html">Preclinical Development</a></li>
      <li><a href="clinical.html">Clinical Trials</a></li>
      <li><a href="regulatory.html">Regulatory Approval</a></li>
      <li><a href="post_marketing.html">Post-Marketing Surveillance</a></li>
    </ul>
  </nav>

  <main>
    <section>
 <h2>Target Validation: A Multi-Dimensional Framework</h2>

  <div class="section">
    <h2>1. Genetic and Genomic Validation</h2>
    <ul>
      <li><strong>GWAS:</strong> Identify SNPs linked to disease traits.</li>
      <li><strong>Rare Variant Analysis:</strong> Pinpoint high-impact mutations in monogenic disorders.</li>
      <li><strong>CRISPR Screens:</strong> Assess phenotypic impact of gene disruption.</li>
      <li><strong>eQTL Mapping:</strong> Correlate genetic variants with expression changes.</li>
    </ul>
    <p><em>Example:</em> SOD1 mutations in familial ALS validate it as a gene-silencing target.</p>
  </div>

  <div class="section">
    <h2>2. Functional and Phenotypic Validation</h2>
    <h3>In Vitro</h3>
    <ul>
      <li>Gain/loss-of-function studies in disease-relevant cell lines.</li>
      <li>Reporter assays to monitor downstream signaling.</li>
      <li>Phenotypic screens using chemical probes or fragments.</li>
    </ul>
    <h3>In Vivo</h3>
    <ul>
      <li>Knockout/knock-in mouse models for physiological relevance.</li>
      <li>Humanized models for immuno-oncology targets.</li>
      <li>Organoids and iPSC-derived systems for personalized validation.</li>
    </ul>
    <p><em>Example:</em> PD-1 blockade in murine tumor models led to checkpoint inhibitor development.</p>
  </div>

  <div class="section">
    <h2>3. Structural and Biophysical Validation</h2>
    <ul>
      <li>X-ray crystallography, cryo-EM, NMR to resolve atomic-level interactions.</li>
      <li>Fragment screening to identify ligandable pockets and cryptic sites.</li>
      <li>SPR, ITC, DSF to quantify binding affinity and thermodynamics.</li>
      <li>HDX-MS and SAXS to probe conformational dynamics.</li>
    </ul>
    <p><em>Example:</em> BCL-2 structure-guided design led to venetoclax.</p>
  </div>

  <div class="section">
    <h2>4. Pathway and Systems-Level Validation</h2>
    <ul>
      <li>Pathway enrichment analysis to map target within disease-relevant cascades.</li>
      <li>Crosstalk modeling to predict compensatory mechanisms and resistance.</li>
      <li>Multi-omics integration for holistic context.</li>
      <li>Dynamic modeling using Boolean or ODE-based simulations.</li>
    </ul>
    <p><em>Example:</em> PI3K inhibition in cancer required dual targeting due to AKT feedback activation.</p>
  </div>

  <div class="section">
    <h2>5. Translational and Clinical Validation</h2>
    <ul>
      <li>Predictive biomarkers indicate likely response to therapy.</li>
      <li>Pharmacodynamic biomarkers confirm target engagement.</li>
      <li>Prognostic biomarkers reflect disease progression.</li>
      <li>Companion diagnostics enable patient stratification.</li>
      <li>Real-world evidence from EHRs and post-marketing data supports long-term validation.</li>
    </ul>
    <p><em>Example:</em> ALK rearrangements in NSCLC led to targeted therapy and diagnostic co-development.</p>
  </div>

  <div class="section">
    <h2>6. Target Validation Pipeline Summary</h2>
    <table>
      <thead>
        <tr>
          <th>Stage</th>
          <th>Tools & Techniques</th>
          <th>Outcome</th>
        </tr>
      </thead>
      <tbody>
        <tr>
          <td>Genetic Validation</td>
          <td>GWAS, CRISPR, eQTL</td>
          <td>Causal linkage</td>
        </tr>
        <tr>
          <td>Functional Validation</td>
          <td>Cell assays, animal models</td>
          <td>Phenotypic modulation</td>
        </tr>
        <tr>
          <td>Structural Validation</td>
          <td>X-ray, cryo-EM, fragment screening</td>
          <td>Binding site definition</td>
        </tr>
        <tr>
          <td>Systems Biology</td>
          <td>Omics, network modeling</td>
          <td>Pathway relevance</td>
        </tr>
        <tr>
          <td>Clinical Translation</td>
          <td>Biomarkers, diagnostics</td>
          <td>Patient stratification</td>
        </tr>
      </tbody>
    </table>
  </div>




    </section>
  </main>
  <footer>
    <p>&copy; 2025 Drug Discovery Knowledge Base</p>
  </footer>
</body>
</html>
